Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation

被引:15
|
作者
Kalicinski, P
Markiewicz, M
Kaminski, A
Laniewski, P
Ismail, H
Drewniak, T
Szymczak, M
Nachulewicz, P
Jezierska, E
机构
[1] Childrens Mem Hlth Inst, Dept Pediat Surg & Organ Transplantat, PL-04736 Warsaw, Poland
[2] Childrens Mem Hlth Inst, Dept Anesthesia & Intens Care, PL-04736 Warsaw, Poland
关键词
liver transplantation; blood loss; coagulopathy; rFVIIa;
D O I
10.1111/j.1399-3046.2005.00309.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Large blood loss and transfusions during liver transplantation (LTx) may lead to serious complications and have a negative impact on post-transplant mortality and morbidity. In the retrospective study we compared two groups of recipients of primary cadaveric liver transplantation: group I (study group), consisted of 28 patients with preoperative risk of high intraoperative blood loss, including severe uncorrected coagulopathy. This group was given a bolus of recombinant activated factor VII (rFVIIa) just before LTx. Group II (control group) included 61 patients without a particular risk for increased intraoperative blood loss. These patients were not given rFVIIa. We analyzed both groups for: coagulation parameters before, during and after surgery (INR, APTT, factor VII activity), blood and FFP transfusions, operative time, postoperative complications (vascular thrombosis, reoperation for bleeding), postoperative ICU stay, post-transplant hospitalization time and mortality. Patients from the study group (I) had significantly worse coagulation parameters than patients in the control group (II) at the start of the surgical procedure; however, after administration of a bolus of rFVIIa there was immediate correction of coagulation in all recipients. No significant differences in intraoperative blood transfusions were observed between study and control groups (1980 +/- 311.4 mL vs. 1527 +/- 154.2 mL, respectively), operating time (8.7 h vs. 8.9 h) or ICU and hospital stay (7.03 days vs. 6.15 days and 40.89 days vs. 41.1 days). Re-exploration because of bleeding was performed in three patients from group I (10.7%) and in seven patients (11.5%) from group II. No single case of vascular thrombosis was observed in the study group, while in the control group there were three hepatic artery thromboses, two portal vein thromboses and one hepatic vein thrombosis. We conclude that rFVIIa given preoperatively to liver transplant recipients with several risk factors for high intraoperaive bleeding adjusts these patients to a normal risk group, without an increased risk for thrombotic complications.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 50 条
  • [21] Recombinant Factor VIIa in Rescue of Critical Bleeding during Orthotopic Liver Transplantation
    Ramamurthy, Anand
    Gopasetty, Mahesh
    Khakhar, Anand K.
    LIVER TRANSPLANTATION, 2012, 18 : S169 - S169
  • [22] Cadaveric liver transplantation in a Jehovah's Witness patient with recombinant activated factor VII.
    Teruya, A
    Takaoka, F
    Oliveira, AP
    Mies, S
    LIVER TRANSPLANTATION, 2005, 11 (07) : C9 - C9
  • [23] Bloodless Liver Transplantation: Rotem Guided Rational Prophylactic Use of Recombinant Activated Factor VII
    Fayed, Nirmeen A.
    Hegazy, Osama A.
    Tanaka, Koichi K.
    LIVER TRANSPLANTATION, 2012, 18 : S181 - S182
  • [24] Risk Factors and Outcomes of Intracardiac Thrombosis During Orthotopic Liver Transplantation
    Al-Darzi, W.
    El-Atrache, M.
    Georgie, F.
    Sadiq, O.
    Singla, S.
    Fernandez, C.
    Pompa, R.
    Galusca, D.
    Yoshida, A.
    Jafri, S. -M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 582 - 582
  • [25] Risk Factors and Outcomes of Intracardiac Thrombosis During Orthotopic Liver Transplantation
    Al-Darzi, Waleed
    Alalwan, Yusuf
    Askar, Firas
    Sadiq, Omar
    Venkat, Deepak
    Gonzalez, Humberto
    Galusca, Dragos
    Yoshida, Atsushi
    Jafri, Syed-Mohammed
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (01) : 250 - 254
  • [26] Predicting Hepatectomy Blood Loss and Operative Time during Orthotopic Liver Transplantation
    Rana, A. A.
    Petrowsky, H.
    Hong, J. C.
    Agopian, V. G.
    Zarrinpar, A.
    Kaldas, F. M.
    Yersiz, H.
    Farmer, D. G.
    Hiatt, J. R.
    Busuttil, R. W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 64 - 64
  • [27] Prophylactic Recombinant Factor VIIa for Preventing Massive Transfusion During Orthotopic Liver Transplantation
    Yang, Muyue
    Ariyo, Promise
    Perlstein, Brooke
    Latif, Asad
    Frank, Steven M.
    Merritt, William T.
    Cameron, Andrew M.
    Philosophe, Benjamin
    Gottschalk, Allan
    Pustavoitau, Aliaksei
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2022, 20 (09) : 817 - 825
  • [28] Prophylactic Activated Recombinant Factor VII in Liver Resection and Liver Transplantation: Systematic Review and Meta-Analysis
    Chavez-Tapia, Norberto C.
    Alfaro-Lara, Roberto
    Tellez-Avila, Felix
    Barrientos-Gutierrez, Tonatiuh
    Gonzalez-Chon, Octavio
    Mendez-Sanchez, Nahum
    Uribe, Misael
    PLOS ONE, 2011, 6 (07):
  • [29] Coagulation Management During Liver Transplantation: Use of Fibrinogen Concentrate, Recombinant Activated Factor VII, Prothrombin Complex Concentrate, and Antifibrinolytics
    Chow, Jonathan H.
    Lee, Khang
    Abuelkasem, Ezeldeen
    Udekwu, Obi R.
    Tanaka, Kenichi A.
    SEMINARS IN CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2018, 22 (02) : 164 - 173
  • [30] Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation
    de Otero, J
    Gavaldà, J
    Murio, E
    Vargas, V
    Calicó, I
    Llopart, L
    Rosselló, J
    Margarit, C
    Pahissa, A
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) : 865 - 870